Skip to main content

Table 4 Therapy-associated toxicity by grade per patient

From: Combination therapy with Olaratumab/doxorubicin in advanced or metastatic soft tissue sarcoma -a single-Centre experience

Event

Any grade

Grade 3

Grade ≥ 4

Any toxicity n (%)

 Nausea Nausea

11 (34.4)

0 (0)

0 (0)

 Fatigue

16 (50)

1 (3.1)

0 (0)

 Neutropenia

15 (47)

2 (6.3)

10 (31.3)

 Mucositis

6 (18.7)

1 (3.1)

0 (0)

 Alopecia Alopecia

32 (100)

0 (0)

0 (0)

 Vomiting

5 (15.6)

0 (0)

0 (0)

 Anaemia Anaemia

29 (90.6)

7 (21.9)

0 (0)

 Leukopenia Leukopenia

21 (65.6)

10 (31.3)

2 (6.3)

 Constipation

7 (21.9)

0 (0)

0 (0)

 Diarrhea Diarrhea

2 (6.3)

0 (0)

0 (0)

 Decreased appetite Decreased appetite

10 (31.3)

0 (0)

0 (0)

 Abdominal pain

3 (3.4)

1 (3.1)

1 (3.1)

 Pyrexia

3 (9.4)

0 (0)

2 (6.3)

 Musculoskeletal pain

2 (6.3)

0 (0)

0 (0)

 Febrile neutropenia

4 (12.5)

1 (3.1)

2 (6.3)

 Infections and infestations

7 (21.9)

1 (3.1)

3 (9.4)

 Infusion-related reaction

1 (3.1)

0 (0)

0 (0)

 Olaratumab-related toxicitiy

0 (0)

0 (0)

0 (0)

 Toxicity leading to discontinuation

1 (3.1)

0 (0)

1 (3.1)

 Cardiac dysfunction

0 (0)

0 (0)

0 (0)

  1. Toxicity was assessed according to the National Cancer Institute (NCI) criteria v5.0